ITI Pharma & Healthcare Fund - Growth - Regular Plan

Other Plans and Options
  • (-3.04%)Nav, as on 07-04-2025

  • Previous Nav

  • Net Change on 07-04-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
Nifty Healthcare Index - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 8.82 16.72 26.16 1.82 7,637.04
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option Jul 13, 2018 14.93 21.05 29.04 1.94 4,611.47
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 15.07 21.28 28.10 1.95 3,312.89
DSP Healthcare Fund - Regular Plan - Growth Nov 30, 2018 10.51 17.65 27.36 1.93 2,950.74
Mirae Asset Healthcare Fund -Regular Growth Jul 02, 2018 12.51 15.99 26.76 1.96 2,441.13

Fund Holdings as on 28-February-2025

  • Sun Pharmaceutical Industries Limited

  • Lupin Limited

  • Suven Pharmaceuticals Limited

  • Divi's Laboratories Limited

  • Apollo Hospitals Enterprise Limited

  • Aurobindo Pharma Limited

  • Max Healthcare Institute Limited

  • Torrent Pharmaceuticals Limited

  • Dr. Reddy's Laboratories Limited

  • Mankind Pharma Limited

  • Alkem Laboratories Limited

  • Aster DM Healthcare Limited

  • Neuland Laboratories Limited

  • Granules India Limited

  • Syngene International Limited

  • Wockhardt Limited

  • Orchid Pharma Limited

  • Healthcare Global Enterprises Limited

  • Fortis Healthcare Limited

  • Caplin Point Laboratories Limited

  • Sumitomo Chemical India Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Gland Pharma Limited

  • Shilpa Medicare Limited

  • FDC Limited

  • Supriya Lifescience Limited

  • Emcure Pharmaceuticals Limited

  • Sequent Scientific Limited

  • TREPS 03-Mar-2025

  • Abbott India Limited

  • Cipla Limited

  • Net Receivables / (Payables)

  • Yatharth Hospital And Trauma Care Services Limited

  • Sai Life Sciences Limited

  • Vijaya Diagnostic Centre Limited

  • UPL Limited

  • SRF Limited

  • Rainbow Childrens Medicare Limited

  • Linde India Limited

  • Strides Pharma Science Limited

  • Onesource Specialty Pharma Limited

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Pesticides & Agrochemicals

  • Miscellaneous

  • Business Support

  • Chemicals

  • Industrial Gases & Fuels

View More

Fund Manager

  • Cash

  • Equity

View More

About ITI Pharma & Healthcare Fund

Scheme Analysis

ITI Pharma & Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ITI Mutual Fund. It was launched on 08-Nov-2021 and currently has an AUM of ₹200.83 crore. ITI Pharma & Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and Nifty Healthcare Index - TRI as secondary index.

The NAV of ITI Pharma & Healthcare Fund ended down ₹-0.46(-3.04%)yesterday to ₹14.7693.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The ITI Pharma & Healthcare Fund is managed by Dhimant Shah and Rohan Korde.

Fund House Contact

ITI House, 36, R K Shirodkar Marg, Parel Mumbai - 400 012

022-69153500
mfassist@itiorg.com
www.itiamc.com